{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:41Z","timestamp":1782337241802,"version":"3.54.5"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jiph.2026.103164","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:28:12Z","timestamp":1770164892000},"page":"103164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Next-generation gene therapy for infectious disease: Advances, challenges, and future directions"],"prefix":"10.1016","volume":"19","author":[{"given":"Maryam","family":"Fattahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Pirbadami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Motallebirad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynab","family":"Beheshti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7641-7035","authenticated-orcid":false,"given":"Davood","family":"Azadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2026.103164_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41434-024-00501-w","article-title":"The disparate burden of infectious diseases","volume":"321","author":"Bloom","year":"2025","journal-title":"Gene Ther"},{"key":"10.1016\/j.jiph.2026.103164_bib2","article-title":"Gene therapy: principles, challenges and use in clinical practice","volume":"11","author":"Ay","year":"2024","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jiph.2026.103164_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1089\/hum.2023.123","article-title":"Recent advances using genetic therapies against infectious diseases and for vaccination","volume":"3417-18","author":"Galy","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.jiph.2026.103164_bib4","first-page":"285","article-title":"The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers","volume":"34","author":"Hong","year":"2018","journal-title":"Educ Inf"},{"key":"10.1016\/j.jiph.2026.103164_bib5","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"3155819","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jiph.2026.103164_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-4939-2687-9_4","article-title":"Annotation and classification of CRISPR-Cas systems","author":"Makarova","year":"2015","journal-title":"CRISPR Methods Protoc"},{"key":"10.1016\/j.jiph.2026.103164_bib7","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1016\/j.csbj.2023.09.005","article-title":"HIV infection detection using CRISPR\/Cas systems: present and future prospects","volume":"21","author":"Deng","year":"2023","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.jiph.2026.103164_bib8","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3390\/ijms24021563","article-title":"A CRISPR-Cas Cure for HIV\/AIDS","volume":"242","author":"Hussein","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiph.2026.103164_bib9","first-page":"865","article-title":"Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza","volume":"1814","author":"Abbott","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jiph.2026.103164_bib10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s12033-022-00639-1","article-title":"A review on advanced CRISPR-based genome-editing tools: base editing and prime editing","volume":"656","author":"Saber Sichani","year":"2023","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.jiph.2026.103164_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11684-023-1013-y","article-title":"Base editors: development and applications in biomedicine","volume":"173","author":"Liang","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.jiph.2026.103164_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40259-023-00610-9","article-title":"Base editing and prime editing: potential therapeutic options for rare and common diseases","volume":"374","author":"Testa","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.jiph.2026.103164_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"243","author":"Chen","year":"2023","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jiph.2026.103164_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2021.734436","article-title":"Programmable base editing in Mycobacterium tuberculosis using an engineered CRISPR RNA-guided cytidine deaminase","volume":"3","author":"Ding","year":"2021","journal-title":"Front Genome Ed"},{"key":"10.1016\/j.jiph.2026.103164_bib15","first-page":"351","article-title":"Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo","author":"Smekalova","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jiph.2026.103164_bib16","article-title":"Staphylococcus aureus nt5 gene mutation through CRISPR RNA-guided base editing weakens bacterial virulence and immune evasion","volume":"161","author":"Liu","year":"2025","journal-title":"Virulence"},{"key":"10.1016\/j.jiph.2026.103164_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2023.09.019","article-title":"Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers","volume":"801","author":"Zhang","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jiph.2026.103164_bib18","article-title":"Emerging strategies and therapeutic innovations for combating drug resistance in Staphylococcus aureus strains: a comprehensive review","volume":"645","author":"Gopikrishnan","year":"2024","journal-title":"J Basic Microbiol"},{"key":"10.1016\/j.jiph.2026.103164_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jiph.2026.103164_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/mps4010010","article-title":"Recent advances in miRNA delivery systems","volume":"41","author":"Dasgupta","year":"2021","journal-title":"Methods Protoc"},{"key":"10.1016\/j.jiph.2026.103164_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/bioengineering11010022","article-title":"A genetic circuit design for targeted viral RNA degradation","volume":"111","author":"Bello","year":"2023","journal-title":"Bioengineering"},{"key":"10.1016\/j.jiph.2026.103164_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","article-title":"The many pathways of RNA degradation","volume":"1364","author":"Houseley","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jiph.2026.103164_bib23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","article-title":"Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents","volume":"396","author":"Blanchard","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jiph.2026.103164_bib24","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1038\/srep02510","article-title":"Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus","volume":"31","author":"Ebina","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2026.103164_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.2507","article-title":"Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease","volume":"313","author":"Cho","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jiph.2026.103164_bib26","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.ymthe.2017.04.027","article-title":"CRISPR\/Cas9-mediated CCR5 ablation in human hematopoietic stem\/progenitor cells confers HIV-1 resistance in vivo","volume":"258","author":"Xu","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jiph.2026.103164_bib27","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia","volume":"2613","author":"Xu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103164_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation","volume":"5687751","author":"Gupta","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jiph.2026.103164_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/biotech11030025","article-title":"Closing the door with CRISPR: genome editing of CCR5 and CXCR4 as a potential curative solution for HIV","volume":"113","author":"Freen-van Heeren","year":"2022","journal-title":"BioTech"},{"key":"10.1016\/j.jiph.2026.103164_bib30","unstructured":"ClinicalTrials.gov. A Study of EBT-101 in Aviremic HIV-1 Participants with HIV-1 Proviral DNA. Identifier: NCT05144386. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05144386\u3009. 2024."},{"key":"10.1016\/j.jiph.2026.103164_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.omtm.2022.02.010","article-title":"A combinatorial CRISPR-Cas12a attack on HIV DNA","volume":"25","author":"Fan","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jiph.2026.103164_bib32","article-title":"CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice","volume":"12019","author":"Dash","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jiph.2026.103164_bib33","unstructured":"ClinicalTrials.gov. A Study of Anti-HIV DuoCAR-T Cell Therapy for HIV Infection. Identifier: NCT04648046. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT04648046\u3009. Accessed December 13, 2025."},{"key":"10.1016\/j.jiph.2026.103164_bib34","article-title":"In vivo killing of primary HIV-infected cells by peripheral-injected early memory\u2013enriched anti-HIV duoCAR T cells","volume":"721","author":"Anthony-Gonda","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jiph.2026.103164_bib35","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"2611","author":"Maldini","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jiph.2026.103164_bib36","article-title":"Anti\u2013PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers","volume":"1347","author":"Eichholz","year":"2024","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jiph.2026.103164_bib37","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41467-020-19649-1","article-title":"Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion","volume":"111","author":"Nahmad","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiph.2026.103164_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41392-022-01269-4","article-title":"B cell engineering in vivo: Accelerating induction of broadly neutralizing antibodies against HIV-1 infection","volume":"81","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jiph.2026.103164_bib39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","article-title":"In-depth virological and immunological characterization of HIV-1 cure after CCR5\u039432\/\u039432 allogeneic hematopoietic stem cell transplantation","volume":"293","author":"Jensen","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jiph.2026.103164_bib40","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","article-title":"HIV-1 remission and possible cure in a woman after haplo-cord blood transplant","volume":"1866","author":"Hsu","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jiph.2026.103164_bib41","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1038\/s41591-024-03277-z","article-title":"Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells","volume":"3012","author":"Saez-Cirion","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jiph.2026.103164_bib42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41467-025-55873-3","article-title":"High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infection","volume":"161","author":"Claiborne","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiph.2026.103164_bib43","doi-asserted-by":"crossref","first-page":"26077","DOI":"10.3390\/ijms161125950","article-title":"Application of CRISPR\/Cas9 Technology to HBV","volume":"1611","author":"Lin","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiph.2026.103164_bib44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.omtm.2020.11.014","article-title":"CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice","volume":"20","author":"Stone","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jiph.2026.103164_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.665184","article-title":"Inhibition of hepatitis B virus by AAV8-derived CRISPR\/SaCas9 expressed from liver-specific promoters","volume":"12","author":"Yan","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jiph.2026.103164_bib46","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/hep4.1933","article-title":"Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing","volume":"67","author":"Zhou","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jiph.2026.103164_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105618","article-title":"Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models","volume":"215","author":"Yi","year":"2023","journal-title":"Antivir Res"},{"key":"10.1016\/j.jiph.2026.103164_bib48","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/hum.2018.007","article-title":"Gene therapy in lipoprotein lipase deficiency: case report on the first patient treated with alipogene tiparvovec under daily practice conditions","volume":"294","author":"Kassner","year":"2018","journal-title":"Hum gene Ther"},{"key":"10.1016\/j.jiph.2026.103164_bib49","article-title":"First-in-Human Study of RG6346 in Participants With Chronic Hepatitis B Infection","author":"ClinicalTrials.gov","year":"2024","journal-title":"Identifier"},{"key":"10.1016\/j.jiph.2026.103164_bib50","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","article-title":"Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials","volume":"794","author":"Gane","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jiph.2026.103164_bib51","unstructured":"ClinicalTrials.gov. A Study of VIR-2218 in Participants With Chronic Hepatitis B Virus Infection. Identifier: NCT03672188. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03672188\u3009. 2021."},{"key":"10.1016\/j.jiph.2026.103164_bib52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40268-021-00369-w","article-title":"Clinical and preclinical single-dose pharmacokinetics of VIR-2218, an RNAi therapeutic targeting HBV infection","volume":"21","author":"Gupta","year":"2021","journal-title":"Drugs RD"},{"key":"10.1016\/j.jiph.2026.103164_bib53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41392-024-01871-8","article-title":"Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection","volume":"91","author":"Zai","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jiph.2026.103164_bib54","unstructured":"ClinicalTrials.gov. A Trial to Evaluate the Efficacy and Safety of Multiple Combination Therapies in Participants With Chronic Hepatitis B (Piranga). Identifier: NCT04225715. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT04225715\u3009. 2025."},{"key":"10.1016\/j.jiph.2026.103164_bib55","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B","volume":"39122","author":"Hou","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103164_bib56","unstructured":"Brian Cosgrove. Tune Therapeutics. TUNE-401: Epigenetic editing for the treatment of HBV [Internet]. 2023 [Available from: \u3008https:\/\/tunetx.com\/wp-content\/uploads\/2023\/12\/HEPDART_Dec5_Web.pdf\u3009."},{"key":"10.1016\/j.jiph.2026.103164_bib57","article-title":"Augmented epigenetic repression of hepatitis B virus covalently closed circular DNA by interferon-\u03b1 and small-interfering RNA synergy","volume":"1512","author":"Hu","year":"2024","journal-title":"Mbio"},{"key":"10.1016\/j.jiph.2026.103164_bib58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41420-021-00515-y","article-title":"Epigenetic reprogramming promotes the antiviral action of IFN\u03b1 in HBV-infected cells","volume":"71","author":"Gailhouste","year":"2021","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jiph.2026.103164_bib59","first-page":"3856","article-title":"Reprogrammed CRISPR-Cas13a targeting the HPV16\/18 E6 gene inhibits proliferation and induces apoptosis in E6-transformed keratinocytes","volume":"196","author":"Li","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jiph.2026.103164_bib60","article-title":"Applications of the versatile CRISPR-Cas13 RNA targeting system","volume":"133","author":"Kordy\u015b","year":"2022","journal-title":"Wiley Interdisciplinary Reviews RNA"},{"key":"10.1016\/j.jiph.2026.103164_bib61","article-title":"E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers","author":"ClinicalTrials.gov","year":"2025","journal-title":"Identifier"},{"key":"10.1016\/j.jiph.2026.103164_bib62","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/pharmaceutics16070880","article-title":"Cationic liposomes carrying HPV16 E6-siRNA inhibit the proliferation, migration, and invasion of cervical cancer cells","volume":"167","author":"S\u00e1nchez-Meza","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiph.2026.103164_bib63","article-title":"Safety and efficacy of PRGN-2012 in adult patients with recurrent respiratory papillomatosis","author":"ClinicalTrials.gov","year":"2025","journal-title":"Identifier"},{"key":"10.1016\/j.jiph.2026.103164_bib64","unstructured":"ClinicalTrials.gov. A Phase 1\/2 Study of INO-3107 in Adult Subjects With Recurrent Respiratory Papillomatosis. Identifier: NCT04398433. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT04398433\u3009. 2024."},{"key":"10.1016\/j.jiph.2026.103164_bib65","article-title":"Ovarian cancer gene therapy using HPV-16 pseudovirion carrying the HSV-tk gene","volume":"77","author":"Hung","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jiph.2026.103164_bib66","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S2213-2600(24)00368-0","article-title":"PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1\/2 clinical trial","volume":"134","author":"Norberg","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jiph.2026.103164_bib67","unstructured":"ClinicalTrials.gov. A Study of HB-202\/HB-201 Therapy in Adults With HPV16+ Confirmed Cancers. Identifier: NCT04180215. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT04180215\u3009. 2025."},{"key":"10.1016\/j.jiph.2026.103164_bib68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/nat.2017.0687","article-title":"Inhibition of human papillomavirus type 16 infection using an RNA aptamer","volume":"282","author":"Valencia-Res\u00e9ndiz","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jiph.2026.103164_bib69","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00216-020-02879-z","article-title":"Reduced graphene oxide\u2013based field effect transistors for the detection of E7 protein of human papillomavirus in saliva","volume":"413","author":"Aspermair","year":"2021","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.jiph.2026.103164_bib70","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1021\/acssensors.3c00677","article-title":"Electrochemical immunosensor for ultra-low detection of human papillomavirus biomarker for cervical cancer","volume":"87","author":"Peteni","year":"2023","journal-title":"ACS Sens"},{"key":"10.1016\/j.jiph.2026.103164_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-021-00455-6","article-title":"Role of CRISPR-Cas system on antibiotic resistance patterns of Enterococcus faecalis","volume":"20","author":"Gholizadeh","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jiph.2026.103164_bib72","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1073\/pnas.1500107112","article-title":"Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria","volume":"11223","author":"Yosef","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jiph.2026.103164_bib73","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/00325481.2019.1680052","article-title":"Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents","volume":"1323","author":"Bader","year":"2020","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jiph.2026.103164_bib74","article-title":"Efficient suppression of natural plasmid-borne gene expression in Carbapenem-resistant Klebsiella pneumoniae using a compact CRISPR interference system","volume":"6611","author":"Yao","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103164_bib75","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/crispr.2024.0001","article-title":"CRISPR-Cas9-mediated targeting of multidrug resistance genes in methicillin-resistant staphylococcus aureus","volume":"76","author":"Ates","year":"2024","journal-title":"CRISPR J"},{"key":"10.1016\/j.jiph.2026.103164_bib76","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41467-020-16731-6","article-title":"Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria","volume":"111","author":"Kiga","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiph.2026.103164_bib77","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s42003-024-06754-w","article-title":"Phagemid-based capsid system for CRISPR-Cas13a antimicrobials targeting methicillin-resistant Staphylococcus aureus","volume":"71","author":"Li","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.jiph.2026.103164_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.987656","article-title":"The virulence factor regulator and quorum sensing regulate the type IF CRISPR-Cas mediated horizontal gene transfer in Pseudomonas aeruginosa","volume":"13","author":"Dela Ahator","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jiph.2026.103164_bib79","article-title":"Francisella novicida CRISPR-Cas systems can functionally complement each other in DNA defense while providing target flexibility","volume":"20212","author":"Ratner","year":"2020","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jiph.2026.103164_bib80","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","article-title":"CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy","volume":"18","author":"Xu","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.jiph.2026.103164_bib81","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cmi.2018.03.026","article-title":"Genome engineering of Clostridium difficile using the CRISPR-Cas9 system","volume":"2410","author":"Wang","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiph.2026.103164_bib82","series-title":"Electroporation protocols: microorganism, mammalian system, and nanodevice","first-page":"127","article-title":"Genome editing in Staphylococcus aureus by conditional recombineering and CRISPR\/Cas9-mediated counterselection","author":"Penewit","year":"2019"},{"key":"10.1016\/j.jiph.2026.103164_bib83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymeth.2019.07.024","article-title":"Gene silencing with CRISPRi in bacteria and optimization of dCas9 expression levels","volume":"172","author":"Depardieu","year":"2020","journal-title":"Methods"},{"key":"10.1016\/j.jiph.2026.103164_bib84","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"134","author":"Hammond","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jiph.2026.103164_bib85","article-title":"Antisense oligonucleotides selectively enter human-derived antibiotic-resistant bacteria through bacterial-specific ATP-binding cassette sugar transporter","volume":"3528","author":"Liu","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.jiph.2026.103164_bib86","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/microbiolres16030070","article-title":"Antisense oligonucleotide-capped gold nanoparticles as a potential strategy for tackling antimicrobial resistance","volume":"163","author":"Garza-Cardenas","year":"2025","journal-title":"Microbiol Res"},{"key":"10.1016\/j.jiph.2026.103164_bib87","article-title":"siRNA-AGO2 complex inhibits bacterial gene translation: a promising therapeutic strategy for superbug infection","volume":"63","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jiph.2026.103164_bib88","article-title":"A systematic review of peptide nucleic acids (PNAs) with antibacterial activities: efficacy, potential and challenges","volume":"633","author":"El-Fateh","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2026.103164_bib89","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1128\/AAC.40.8.1801","article-title":"Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria","volume":"408","author":"Vaara","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103164_bib90","article-title":"Antimicrobial activity of peptide-coupled antisense peptide nucleic acids in Streptococcus pneumoniae","volume":"106","author":"Barkowsky","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jiph.2026.103164_bib91","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1021\/bc1003586","article-title":"Cellular delivery and antisense effects of peptide nucleic acid conjugated to polyethyleneimine via disulfide linkers","volume":"2110","author":"Berthold","year":"2010","journal-title":"Bioconjugate Chem"},{"issue":"9","key":"10.1016\/j.jiph.2026.103164_bib92","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1021\/acs.nanolett.8b02166","article-title":"Inhibiting methicillin-resistant Staphylococcus aureus by tetrahedral DNA nanostructure-enabled antisense peptide nucleic acid delivery","volume":"189","author":"Zhang","year":"2018","journal-title":"Nano Lett"},{"key":"10.1016\/j.jiph.2026.103164_bib93","first-page":"933","article-title":"Engineering phages to fight multidrug-resistant bacteria","volume":"1252","author":"Peng","year":"2024"},{"key":"10.1016\/j.jiph.2026.103164_bib94","first-page":"532","article-title":"Construction of a genetically modified T7Select phage system to express the antimicrobial peptide 1018","volume":"576","author":"Lemon","year":"2019"},{"key":"10.1016\/j.jiph.2026.103164_bib95","article-title":"Genetically engineered phages and engineered phage-derived enzymes to destroy biofilms of antibiotics resistance bacteria","volume":"1015","author":"Eghbalpoor","year":"2024"},{"key":"10.1016\/j.jiph.2026.103164_bib96","first-page":"130","article-title":"Bacteriophage-delivering hydrogels: Current progress in combating antibiotic resistant bacterial infection","volume":"102","author":"Kim","year":"2021"},{"key":"10.1016\/j.jiph.2026.103164_bib97","first-page":"175","article-title":"Bacteriophage-derived depolymerases against bacterial biofilm","volume":"102","author":"Topka-Bielecka","year":"2021"},{"key":"10.1016\/j.jiph.2026.103164_bib98","first-page":"35","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial","volume":"191","author":"Jault","year":"2019"},{"key":"10.1016\/j.jiph.2026.103164_bib99","first-page":"730","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"255","author":"Dedrick","year":"2019"},{"key":"10.1016\/j.jiph.2026.103164_bib100","unstructured":"ClinicalTrials.gov. Evaluation of Phage Therapy for the Treatment of Escherichia coli and Pseudomonas aeruginosa Wound Infections in Burned Patients (PHAGOBURN). Identifier: NCT02116010. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT02116010\u3009. 2015."},{"key":"10.1016\/j.jiph.2026.103164_bib101","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease","volume":"761","author":"Dedrick","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2026.103164_bib102","doi-asserted-by":"crossref","unstructured":"Taha E.A., Lee J., Hotta AJJoCR. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. 2022;342:345-361.","DOI":"10.1016\/j.jconrel.2022.01.013"},{"key":"10.1016\/j.jiph.2026.103164_bib103","doi-asserted-by":"crossref","unstructured":"Doxzen K.W., Adair J.E., Fonseca Bazzo Y.M., Bukini D., Cornetta K., Dalal V., et al. The translational gap for gene therapies in low-and middle-income countries. 2024;16746:eadn1902.","DOI":"10.1126\/scitranslmed.adn1902"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:22:44Z","timestamp":1782199364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034126000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1876034126000365"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103164","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation gene therapy for infectious disease: Advances, challenges, and future directions","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"103164"}}